In the present experiments we investigated endothelin (ET) receptors in the human coronary artery, and in ventricular and atrial muscle using quantitative receptor autoradiography. These data indicate that both [125I]ET-1 and [125I] Sf6b-labeled ETA and ETB binding sites in human ventricular and atrial muscle. In the human coronary artery, both radioligands labeled ETA binding sites, but [125I] Sf6b also labeled a non-ET A, non-ETB binding site with relatively high affinity for both ET-1.
Introduction
Endothelin (ET) was originally described as a potent vasoconstrictor peptide (Yanigasawa et al. 1988) . In addition, Fozard and Wright (1988) described a vasodilatory effect, later found to be mediated, at least partially, by an endothelium-dependent mechanism involving the release of nitric oxide (NO; Fukuda et al. 1990 ) and/or prostacyclin (PGI2; De Nucci et al. 1990 ). In the heart, endothelin has been reported to elicit both positive inotropic (Moravec et al. 1989; Kitayoshi et al. 1989; Takanashi and Endoh 1991) and chronotropic (Ishikawa et al. 1989 ) effects. Furthermore, endothelin induced mitogenesis of vascular smooth muscle cells (Komuro et al. 1988; Ohlstein et al. 1992 ) and hypertrophy of myocardial cells (Shubeita et al. 1990 ) indicating that endothelin may play a role in the development of atherosclerosis and cardiac hypertrophy.
Two distinct endothelin receptor subtypes (ETA; Arai et al. 1990 and ETB; Sakurai et al. 1990 ) have been cloned. In radioligand binding studies, the ET A receptor has somewhat higher affinity for ET-I in comparison with isopeptides like ET-3 or sarafotoxin S6b. The ET B receptor has almost equal affinity for all endothelins and sarafotoxin S6b (Arai et al. 1990; Sakurai et al. 1990; Saeki et al. 199/) . The development of selective ligands that distinguish between these receptors has further helped to characterize the receptors present in various tissues such as the lungs (Nakamichi et al. 1992) , kidneys (Nambi et al. 1992 ) and the myocardium (Molenaar et al. 1993) . In the diseased human heart obtained from heart transplant recipients, both ET A and ET B receptors have been described in the atrium and ventricle and in the atrioventricular conducting system, using in situ hybridization and radioligand binding applying [125I]BQ3020, [125I] [AlaI'3'll'lS]ET-1 (both with particularly high affinity for the ET B receptor) and the relatively unselective [125I]ET-1 as radioligands Molenaar et al. 1992 Molenaar et al. , 1993 .
In the present study we characterized endothelin receptors in the human coronary artery, obtained from healthy and diseased hearts. For comparison we also studied endothelin receptors in the human ventricle and human atrium. We used the ETA receptor selective li- Ihara et al. 1991 ) and the ETB receptor selective ligand [Alal'3'lt'lS]ET-1 (Nakamichi et al. 1992 ) and ET-1 to displace binding of the relatively non-selective ligands [125I]ET-1 and [lzSI]Sf6b. A part of this study was presented to the British Pharmacological Society (Bax et al. 1993 ).
site-model, depending on the best fit (based on the Z 2 values, Grafit, Erithacus Software Ltd., Staines, UK). The slope factor of the displacement curves by [Ala~'S'~'~5]ET-1 and BQ-123 in the coronary artery were calculated according to De Lean et al. (1978) , by fitting the curve in a one-receptor model.
Compounds.
[125I]ET-1 and [125IlSf6b (both with specific activity of 2200 Ci/mmol) were purchased from ANAWA (Ztirich, Switzerland). ET-1, [Alal'S'll'tS]ET-I and BQ-123 were purchased from Neosystem S.A. (Strasbourg, France).
Results

Materials and methods
Preparation of the tissue. A total of 16 human hearts was used in the present investigation. All experiments were approved by the Ethical Committee of the University Hospital Rotterdam 'Dijkzigt', The Netherlands. The hearts were provided by the Rotterdam Heart Valve Bank (Bio Implant Services/Eurotransplant Foundation, Leiden, The Netherlands) after removal of the aortic and pulmonary valves for valve transplantation. Twelve of the hearts were obtained from patients who died of non-cardiac disorders (6 cerebrovascular accident, 6 polytrauma; 7 male, 5 female; age 7-55 years). These hearts were stored at 0-4 ° C in a sterile organ protecting solution immediately following circulatory arrest and arrived in the laboratory within 20 h after cardiac arrest. Four hearts were obtained from patients undergoing cardiac transplantation (2 dilating cardiomyopathy, included in the groups of cardiac atrium and ventricle and 2 end-stage coronary artery disease, included in the coronary artery group; all male; age 41-55 years). After arrival in the laboratory, the right and left descending coronary artery and samples of free wall of right atrium and left ventricle (+ 1.5 cm 3) were removed and the vessels were cleaned of fat and connective tissue. All samples were embedded in M-1 embedding matrix (Lipshaw, Pittsburgh PA, USA) and frozen in liquid nitrogen. The tissue was kept at -70 °C until further use. Serial sections of 10 gm were cut on a micro-cryostat and thaw-mounted on gelatin-coated glass slides and kept at -20°C until binding experiments.
Autoradiographic protocol. The slides were thawed and subsequently preincubated for 15 min in a Tris-BSA buffer, pH 7.4. (Tris: tris(hydroxymethyl)-aminomethan; BSA: Bovine Serum Albumin; both from Sigma Chemical Co., St. Louis MO, USA). The tissue was then incubated, at room temperature, for 120 min in 10 ml Tris-BSA buffer containing either 30 pM [lzsI]ET-I or 30 pM [lZSI]Sf6b. The incubation buffer also contained chymostatin (2 mg/1; Bachem, Bubendorf, Switzerland), leupeptin (4 rag/l; Sigma Chemical Co., St. Louis MO, USA), bacitracin (40 rag/l; Sigma, Buchs, Switzerland) and 5 mM MnC1 z. Non-specific binding was assessed in the presence of 0.3 p.M unlabeled ET-1. Displacement of radioligand binding was studied by adding unlabeled ET-1 (concentration range I pM-0.3 IxM), [Alal'3'll'lS]ET-1 (concentration range 30 pM-10 ~M) or BQ-123 (concentration range 3 pM-30 gM) to the radioligand containing buffer. After incubation, the slides were rinsed twice in ice-cold buffer for 5 min. The slides were then rapidly dried by exposing to a stream of cold air and subsequently apposed to [SH] Hyperfilm (Amersham, Buckinghamshire, UK) for 6 h. After exposure the films were developed (Kodak D19, Rochester, New York, USA), fixated and dried. In addition, we performed high resolution autoradiography by placing emulsion-coated (Kodak NTB 3, Rochester, New York, USA) glass coverslips to the slides and exposed for 18 h. The coverslip slides were developed (Kodak D19, Rochester, New York, USA) and fixated. Subsequently the tissue was stained with elastic-Van Gieson. Experiments (n = 7-14) were performed in two separate sessions.
Analys& of the data. Binding on film was quantified densitometrically using a computerized image analysis system (MCID Imaging Research, St. Catherines, Ontario, Canada). Displacement curves were analyzed for individual segments, generating competition curves for a one or two ET-1 (which should equal the proportion of low affinity sites of BQ-123) was 53 +_3°70: 47 +3% in the ventricle; percentages for separate curves: see Table 1 ).
Also in the atrium [t25IlSf6b and [125I]ET-1 were displaced monophasically by ET-1, but biphasically by [Ala s, 3,11, I5]ET_ 1 and BQ-123 ( Fig. 4 ; pICso values of the curves are shown in Table 2 ). In the atrium, the proportion of high affinity sites of BQ-123 as compared to the high affinity sites of [Alat'33~'IS]ET-1 was 68+3070: 32+3070 (percentages for separate curves: see Table 2 ). (Fig. 5) . Taken together, this indicates that the use of ET-1 to define non-specific binding is appropriate.
Endothelin receptors in the ventricle and the atrium
Endothelin has been shown to cause positive inotropic and/or chronotropic effects in the ventricle and atrium of several animal species (Kitayoshi et al. 1989; Ishikawa et al. 1988a, b) and man (Moravec et al. 1989; Davenport et al. 1989; Brodde et al. 1992 ). In the rabbit isolated papillary muscle, the positive inotropic response appeared to be mediated by the ET B receptor (Takanashi and Endoh 1991) , but the nature of the receptor involved in endothelin-induced rat myocyte hypertrophy and secretion of natriuretic peptide from rat myocytes (Shubeita et al. 1990 ) thus far remains unknown. The human ventricle has recently been shown to contain both ET A and ETB receptors, e.g. by using BQ-123 and BQ-3020 (an ET B re- ~_ , ,,,,,,~ ...... . ........ , ,~,,,,,~ , , ,,,,~ ....... 50.l +6.1 plCs0 low 7.24±0.14 % low 49.9 -+ 6.1 a Monophasic complete displacement b plC5 ° value when fitted to a monophasic model to calculate the slope factor of the curve for both the ET A and ETB receptor (Molenaar et al. 1993) . These authors also found a (free wall) ventricular population of both ETA and ETB receptors in an approximate percentage of 60 and 40%, respectively (present study 53 and 47070, respectively). In our study the pICs0 values of ET-1, [Alal'3'll'lS]ET-1 and BQ-123 also fitted with a mixed ETA/ETB receptor population. The high affinity of BQ-123 (pK D -~ 9), presumably for the ET A receptor, was however clearly higher in the study by Molenaar et al. (1993) than in our study (pICs0 ~-7).
Other ET A receptor assays, however, have reported pICs0 values for BQ-123 of approximately 7 (Nakamichi et al. 1992) or 8 . Also in the atrium we observed a mixed receptor population that appeared to consist of both ET A and ET B receptors. In the right atrium, the proportion of ET A receptors (68% ET A vs. 32°70 ETB receptors) was somewhat higher than in the ventricle. This was possibly due to a higher density of atrial ETA receptors and similar density of ET B receptors, since the overall ET receptor density was higher in the atrium. Endothelin has previously been shown to elicit positive inotropic responses in the human isolated atrium (Davenport et al. 1989; Brodde et al. 1992 ). However, ET-1 did not cause positive inotropic affects in six strips obtained from the human ventricle strip that responded normally to (-)-isoprenaline (Davenport et al. 1989 ) and caused only very small inotropic effects in another study (Moravec et al. 1989) . In this respect, it is of interest that the receptor density in the ventricle of several animal species has previously been found to correspond to the effectiveness of ET-1 in producing a positive inotropic effect (Takanashi and Endoh 1991) . Functionally differential effects on human atrial and ventricular tissue have also been observed for 5-hydroxytryptamine which produced a positive inotropic effect on the isolated atrium (Kaumann et al. 1991) which could not be shown in the ventricle (Jahnel et al. 1992; Schoemaker et al. 1992a, b) . Therefore, one should be careful to extrapolate the clear positive inotropic response elicited by endothelin in the rabbit papillary muscle (Takanashi and Endoh 1991) and in the human atrium (Davenport et al. 1989; Brodde et al. 1992) to the human ventricle, until further functional experiments in the human ventricle have been performed.
Endothefin receptors in the coronary artery
Endothelin was originally described as a vasoconstrictor peptide (Yanagisawa et al. 1988) . Since then, various reports have appeared on the nature of this contractile receptor. An ET A receptor appeared to be involved in the contractile response to ET-I of the porcine coronary artery (Fukuroda et al. 1992 ), but a non-ET A receptor, different from the ET n receptor, seemed to be involved as well (Harrison et al. 1992 ). This contention was based on the finding that ET-3 recognized a sarafotoxin $6c (selective for the ET B receptor; Williams et al. 1991 ) sensitive receptor, which was not recognized by ET-I, thus ruling out the ET R receptor. ET-1 has also been shown to cause potent contractions of human coronary artery segments (Chester et al. 1989; Davenport et al. 1989; Hems6n et al. 1990 ), but until now the nature of the endothelin receptor in this particular tissue remains unknown.
The present results indicate that a receptor which shows similar affinities for ET-1, [Alal'3'tl'lS] ET-1 and BQ-123 as in the human ventricle and atrium is also present in the human coronary artery. Using in situ-hybridization to show the presence of mRNA for the receptor, Molenaar et al. (1993) provided further evidence that this endothelin receptor in the human ventricle and atrium is of the ETA subtype. Considering the biphasic and shallow displacement curves (Fig. 5) (Tables 1, 2 ). On the other hand, vascular receptor heterogeneity has previously been suggested by Sumner et al. (1992) , who observed that ET-3-induced contractions of the rabbit thoracic aorta were antagonized by BQ-123 with an estimated pK B value of 8.3, whereas BQ-123 antagonized ET-l-induced contractile responses of the same tissue with a -presumably ET A receptor-related -pA 2 of 6.9.
Endothelin receptors in the diseased heart
When compared to healthy cardiac tissue (Bio Implant Services/Eurotransplant organ donor tissue), we observed no differences in atrial and ventricular endothelin receptor characteristics in diseased hearts (dilating cardiomyopathy, obtained from heart transplant recipients). However, it has to be kept in mind that the numbers of diseased hearts investigated (n = 2) is too small to note possible subtle differences. Other investigators also failed to show a difference between healthy and diseased tissue (Eisenmenger's syndrome, ischemic heart disease; Molenaar et al. 1993) in man. An experimentally induced congestive heart failure in dogs, however, was found to result in a downregulation of cardiac endothelin receptors, possibly due to an increased plasma endothelin level (Fan et al. 1992 ). An increased plasma endothelin level has also been noticed in a variety of human cardiovascular (and non-cardiovascular) diseases in man (Miller et al. 1993 ).
In the human coronary artery obtained from cardiac transplantation patients for ischemic heart disease (n = 2), we have neither observed a higher density of receptors nor different receptor characteristics. However, it has to be remarked that the pathological changes in coronary artery diseased transplantation hearts are merely the end-stage of a disease, present in the vasculature of many subjects who are generally considered healthy.
In summary, we observed that both [125I]ET-1 and [125I]Sf6b were found to label a population of ET A and ETB binding sites in the human ventricle and atrium. Using [125I]ET-1 we found a single receptor population in the human coronary artery with similar characteristics as the ET A receptor in the ventricle and atrium. However, the radioligand [t25I]Sf6b also labeled a binding site with characteristics different from the atrial and ventricular endothelin receptors. Further experiments are needed to demonstrate whether this binding site is indeed a new endothelin receptor in the human coronary artery.
